Cyprium to Sell Rare Disease Priority Review Voucher for $205 Million
Fortress Biotech’s subsidiary Cyprium Therapeutics agreed to sell its Rare Pediatric Disease Priority Review Voucher for gross proceeds of $205 million upon closing. Cyprium retains eligibility for tiered royalties on ZYCUBO net sales and up to $129 million in milestones while paying the NIH 20% of PRV proceeds.
1. PRV Sale Agreement
Cyprium Therapeutics entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher for gross proceeds of $205 million, subject to customary closing conditions including expiration of the HSR antitrust waiting period.
2. ZYCUBO Approval and Transfer
The PRV was issued upon FDA approval of ZYCUBO (copper histidinate) on January 12, 2026, and transferred to Cyprium per the December 2023 agreement under which Sentynl Therapeutics assumed development and commercialization of the therapy.
3. Economic Terms
Under the transaction, Cyprium will pay 20% of PRV sale proceeds to the Eunice Kennedy Shriver National Institute of Child Health and Human Development, remain eligible for tiered royalties on ZYCUBO net sales, and can earn up to $129 million in development and sales milestones.
4. Strategic Context
This monetization follows three FDA approvals for Emrosi™, UNLOXCYT™, and ZYCUBO in the past 15 months and the sale of Checkpoint Therapeutics, reflecting Fortress Biotech’s focus on value-generating asset transactions and pipeline advancement.